* Contribute to the development and execution of a US customer level business plan in order to maximize the launch of Glatopa 40mg/mL into the US neurology market
* Contribute to the strategic segmentation of the US neurology market for Glatopa 40mg/mL and identification of target customers
Dew is correct - at risk 40mg. launch seems quite likely for 2/2017 if FDA approval is granted this year.